Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF

Abstract Background Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a common co-morbidity in heart failure with preserved ejection fraction...

Full description

Bibliographic Details
Main Authors: David Bode, Lukas Semmler, Paulina Wakula, Niklas Hegemann, Uwe Primessnig, Nicola Beindorff, David Powell, Raphael Dahmen, Hartmut Ruetten, Christian Oeing, Alessio Alogna, Daniel Messroghli, Burkert M. Pieske, Frank R. Heinzel, Felix Hohendanner
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Cardiovascular Diabetology
Subjects:
Atrial cardiomyopathy
Heart failure with preserved ejection fraction
SGLT inhibition
Atrial remodeling
Left atrial cardiomyocytes
Calcium cycling
Online Access:https://doi.org/10.1186/s12933-020-01208-z

Internet

https://doi.org/10.1186/s12933-020-01208-z

Similar Items